Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase 1b/2 Study Investigating Safety, Tolerability, Pharmacokinetics and Preliminary Antitumor Activity of Anti-HER2 Bispecific Antibody ZW25 in Combination With Chemotherapy With/Without Tislelizumab in Patients With Advanced HER2-positive Breast Cancer or Gastric/Gastroesophageal Junction Adenocarcinoma

NCT04276493 is registered in ClinicalTrials.gov with BeiGene as lead sponsor.

NCT NCT04276493
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04276493 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase 1b/2 Study Investigating Safety, Tolerability, Pharmacokinetics and Preliminary Antitumor Activity of Anti-HER2 Bispecific Antibody ZW25 in Combination With Chemotherapy With/Without Tislelizumab in Patients With Advanced HER2-positive Breast Cancer or Gastric/Gastroesophageal Junction Adenocarcinoma
Lead sponsor
BeiGene
Phase
Phase 1/2
Overall status
Completed
Start date
March 23, 2020
Completion date
October 31, 2024
Enrollment
71 (actual)
Sites
21

Conditions

As the registry lists them; a condition with its own page is linked.

breast cancer, gastric cancer, gastroesophageal junction cancer